Denufosol tetrasodium Inhalation Solution
( DrugBank: Denufosol / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
299 | 嚢胞性線維症 | 9 |
299. 嚢胞性線維症
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
Showing 1 to 9 of 9 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01181622 (ClinicalTrials.gov) | August 201020100800 | 12/8/201020100812 | A Safety and Tolerability Study of Denufosol in 2-4 Year Olds | A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety and Tolerability Study of Denufosol Tetrasodium Inhalation Solution Administered Via PARI LC® Star in Patients 2 to 4 Years of Age With Cystic Fibrosis A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety ... | Cystic Fibrosis | Drug: denufosol tetrasodium Inhalation Solution;Drug: 0.9% w/v sodium chloride solution | Merck Sharp & Dohme Corp. | NULL | Completed | 2 Years | 4 Years | Both | 25 | Phase 2 | United States |
2 | NCT00846781 (ClinicalTrials.gov) | February 200920090200 | 18/2/200920090218 | Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642) Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium In ... | Cystic Fibrosis | Drug: Denufosol tetrasodium Inhalation Solution | Merck Sharp & Dohme Corp. | NULL | Terminated | 5 Years | N/A | Both | 308 | Phase 3 | United States;Australia;Canada;New Zealand | |
3 | NCT00625612 (ClinicalTrials.gov) | February 200820080200 | 12/2/200820080212 | Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease Study of Denufosol Tetrasodium Inhalation Solutionin Patients With Cystic Fibrosis (CF) Lung Disease ... | A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease and FEV1 Greater Than or Equal to 75% Predicted But Less Than or Equal to 110% Predicted A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group ... | Cystic Fibrosis | Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution;Drug: Placebo | Merck Sharp & Dohme Corp. | NULL | Completed | 5 Years | N/A | Both | 466 | Phase 3 | United States;Australia;Canada;New Zealand |
4 | NCT00425165 (ClinicalTrials.gov) | July 200720070700 | 19/1/200720070119 | Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease Study of Denufosol Inhalation Solutionin Patients With Mild to Moderate Cystic Fibrosis Lung Disease ... | A Randomized, Double-Blind, Two Way Crossover Evaluation of the Effects of a Single Dose of Denufosol Tetrasodium (INS37217) Inhalation Solution Versus Placebo (0.9% Sodium Chloride Solution) on Mucociliary Clearance in Patients With Mild to Moderate Cystic Fibrosis Lung Disease A Randomized, Double-Blind, Two Way Crossover Evaluation of the Effects of a Single Dose of Denufoso ... | Cystic Fibrosis | Drug: denufosol tetrasodium (INS37217) Inhalation Solution | Merck Sharp & Dohme Corp. | NULL | Terminated | 10 Years | N/A | Both | 6 | Phase 2 | United States |
5 | NCT00357279 (ClinicalTrials.gov) | July 200620060700 | 25/7/200620060725 | Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease | A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol ... | Cystic Fibrosis | Drug: denufosol tetrasodium (INS37217) Inhalation Solution;Drug: Placebo - 0.9% w/v sodium chloride solution Drug: denufosol tetrasodium(INS37217) Inhalation Solution;Drug: Placebo - 0.9% w/v sodium chloride s ... | Merck Sharp & Dohme Corp. | NULL | Completed | 5 Years | N/A | Both | 352 | Phase 3 | United States;Canada |
6 | NCT00130182 (ClinicalTrials.gov) | August 200520050800 | 11/8/200520050811 | A Study in Pediatric Patients With Cystic Fibrosis Lung Disease | A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Pediatric Patients With Cystic Fibrosis Lung Disease A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium(INS37217) Inha ... | Cystic Fibrosis | Drug: denufosol tetrasodium (INS37217) | Merck Sharp & Dohme Corp. | NULL | Completed | 5 Years | 7 Years | Both | 13 | Phase 2 | United States |
7 | NCT00103714 (ClinicalTrials.gov) | January 200520050100 | 14/2/200520050214 | Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease | A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Cystic Fibrosis Lung Disease A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium( ... | Cystic Fibrosis | Drug: denufosol tetrasodium (INS37217) | Merck Sharp & Dohme Corp. | NULL | Completed | 8 Years | 50 Years | Both | 72 | Phase 2 | United States |
8 | NCT00056147 (ClinicalTrials.gov) | April 200320030400 | 6/3/200320030306 | Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease | Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects With Mild to Moderate Cystic Fibrosis Lung Disease Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solu ... | Cystic Fibrosis | Drug: denufosol tetrasodium (INS37217) | Merck Sharp & Dohme Corp. | Cystic Fibrosis Foundation Therapeutics | Completed | 8 Years | 50 Years | Both | 90 | Phase 2 | United States |
9 | NCT00034515 (ClinicalTrials.gov) | June 200120010600 | 29/4/200220020429 | A Study in Adult and Pediatric Patients With Cystic Fibrosis | Ph 1b/2a Study to Assess Levels of INS37217 and Placebo Treatment With Maximum Tolerated Dose Administered by Inhalation Via the Pari LC Star Nebulizer in Adult and Pediatric CF Patients Ph 1b/2a Study to Assess Levels of INS37217 and Placebo Treatment With Maximum Tolerated Dose Admini ... | Cystic Fibrosis | Drug: denufosol tetrasodium (INS37217) Inhalation Solution | Merck Sharp & Dohme Corp. | NULL | Completed | 5 Years | N/A | Both | 63 | Phase 1/Phase 2 | United States |